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Abstract
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The inducible isoform of nitric-oxide synthase (iNOS) is involved in neuropathogenesis associated
with infection and disease in the brain. Hence, there is considerable interest in the identification of
therapeutic interventions to prevent iNOS-mediated pathology. Astroglia are a major site of iNOS
expression during neuropathogenesis. To mimic a key component of neuroinflammation, human
A172 astroglial cells were exposed in vitro to a cytokine mixture containing interferon γ, tumor
necrosis factor α, and interleukin-1β, resulting in significant iNOS expression. Next, we assessed
the effects of the mu opioid receptor antagonist, β-funaltrexamine (β-FNA), on cytokine induced
iNOS expression in human astroglia. β-FNA dose-dependently inhibited iNOS expression. β-FNA
transcriptionally (or pre-transcriptionally) inhibited cytokine-induced iNOS activation as indicated
by a significant decrease in NOS2 messenger RNA expression. Further characterization of the
novel, anti-inflammatory actions of β-FNA may provide insights for pharmacologic strategies to
treat or prevent brain pathologies associated with neuroinflammation.
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Introduction
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Increasing evidence suggests that the inducible isoform of nitric-oxide synthase (iNOS) is
instrumental in the neuropathogenesis associated with infection (Poluektova et al. 2005)
trauma (Louin et al. 2006) and neurodegenerative diseases (Marchetti et al. 2005). While not
typically expressed in the central nervous system (CNS) under physiological conditions,
iNOS is transcriptionally induced by various stimuli associated with pathologic insults
including, hypoxia, bacterial components, viral proteins, and cytokines. Once expressed,
iNOS catalyzes the nicotinamide adenine dinucleotide phosphate-dependent oxidation of Larginine to nitric oxide (NO) and citrulline. Unlike other NOS isoforms, iNOS has
continuously high and long-lasting activity and, depending on the temporal expression and
cellular context, can either be neurotoxic or neuroprotective. Increased iNOS activation
associated with infection is typically neuroprotective given the role of NO in the destruction
of infectious organisms. Whereas, sustained iNOS activation in the CNS is predominantly
detrimental resulting in neurotoxicity and cognitive deficit. Therefore, there is an interest in
identifying therapeutic strategies to attenuate excessive iNOS expression and activity,
thereby reducing further neuropathogenesis (Jafarian-Tehrani et al. 2005; Louin et al. 2006).
For instance, administration of 1400W (a selective inhibitor of iNOS) within 18 h of
traumatic brain injury reduces neuropathogenic insult (Jafarian-Tehrani et al. 2005). More
recently, opioids such as morphine have gained attention for their potential neuroprotective
actions (Zhao et al. 2006). However, very little is known about the specific effects of opioids
on iNOS activation in astroglia. Additionally, the clinical use of mu opioid receptor (MOR)
agonists such as morphine is associated with numerous adverse effects including respiratory
depression, nausea, and dependence. Herein, we have assessed the effects of a non-addictive
opioid agent, the MOR-selective antagonist, β-funaltrexamine (β-FNA), on human astroglial
iNOS expression. We have demonstrated that cytokine-induced iNOS expression in human
astroglial cells is dose-dependently inhibited by β-FNA. Evidence for a pretranslational
mechanism of action is presented and discussed; to our knowledge, this is the first report of
iNOS inhibition by β-FNA.

Materials and methods
Cell culture
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The human astrocytoma cell line (A172, ATCC #CRL-1620; American Type Culture
Collection, Manassas, VA, USA) was used to model a key component of
neuroinflammation. A172 cells were maintained as previously described (Davis et al. 2002),
and experimental cultures were seeded at a cell density (1×104/cm2) to provide 80–90%
confluence at the time of treatment.
iNOS induction
Optimal induction of iNOS expression in A172 cells requires co-exposure to a mixture of
cytokines (Davis et al. 2002). Thus, iNOS was induced by 8–24 h exposure to a cytokine
mixture containing 100 ng/ml human recombinant IFNγ (Peprotech Inc., Rocky Hill, NJ), 30
ng/ml human recombinant TNFα (Peprotech), and 5 ng/ml human recombinant IL-1β
(Peprotech). To assess the effects of β-FNA on iNOS expression, β-FNA (0.05–33 μM;
Sigma, St. Louis, MO) was added to cell cultures at the time of cytokine stimulation. Cell
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viability was monitored using the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium
(MTT) assay as previously described (Davis et al. 2007).
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To quantitate iNOS activity, nitrite accumulation in the culture media was determined
spectrophotometrically 24 h post-stimulation using the Griess reagent as previously
described (Davis et al. 2002). Quantitative analysis of NOS2 gene expression was evaluated
using the quantitative real-time polymerase chain reaction (qRT-PCR) and the SYBR green
I reporter assay. Total cellular RNA was collected according to an established procedure
(Davis and Syapin 2004). Primers, forward (5′ GGAGCCAGCTCTGCATTATC 3′) and
reverse (5′ TTTTGTCTCCAAGGGACCAG 3′) were then developed for amplification of a
195-bp region of the iNOS gene (GenBank accession no. NM_000625) using Primer 3
software. The PCR product generated was sequenced to confirm that the amplicon was
iNOS. Two-step reverse transcriptase–polymerase chain reactions (RT-PCR) were
performed. Complementary DNA (cDNA) synthesis was performed using 1 μg of total RNA
using the QuantiTec reverse transcription kit (Qiagen, Valencia, CA, USA), which includes
a DNA removal step to eliminate genomic contamination. Manufacturer’s protocol was
followed with one modification where the cDNA synthesis reaction was incubated for 30
min at 42°C instead of the 15 min described in the protocol. The quantitative gene
expression analysis was performed using the FastStart SYBR green master kit (Roche
Applied Science, Indianapolis, IN, USA) in a Biorad MyiQ detection system (Biorad,
Hercules, CA, USA). A total reaction volume of 15 μl contained 400 nM forward primer,
400 nM reverse primer, 1× master mix, and 40 ng of cDNA. Thermal cycling conditions
were 95°C for 10 min, followed by 45 additional cycles of 95°C for 30 s, 58°C for 30 s, and
72°C for 30 s, and a melting curve to ensure the amplification of a single product.
Ribosomal 18S RNA (18S, RNA control kit, Eurogenetec, Philadelphia, PA, USA) was
assayed according to the manufacturer’s protocol for each sample for normalization.
Relative quantification of gene expression was evaluated using the comparative computed
tomography (CT) method as described previously (Hettinger et al. 2001). The ΔCT value
was determined by subtracting the gene CT value of each sample from the corresponding
sample ribosomal 18S CT value. Calculation of ΔΔCT was carried out by subtracting the
mean ΔCT value obtained for the unstimulated samples from all other ΔCT mean values.
Fold changes in gene expression were then calculated from the ΔΔCT values using the
formula 2−ΔΔCt.
Statistical analysis
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Prism™ version 4.0 software (GraphPad Inc., San Diego, CA) was used for figure
presentation, curve fitting, percent transformations, and statistical analysis. Analyses
included one-way analysis of variance (ANOVA) with Neuman–Kuels multiple comparison
post hoc test as well as nonlinear regression in which the Hill slope was not constrained.
Data are presented as mean + SEM or mean IC50 values. For analysis of iNOS gene
expression, data were analyzed by the least square ANOVA using the Proc Mixed procedure
of the Statistical Analysis Software (SAS 1988). The fixed effect of treatment was analyzed
for iNOS gene expression using ΔCT values. Results are presented as least square means ±
standard error of the mean. A probability (P) of <0.05 was accepted as demonstrating
statistically significant differences between groups. The number of replicate measures and
independent experiments from which the data were obtained are provided in the individual
figure legends.
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Results
β-FNA effects on iNOS activity
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β-FNA potently inhibited cytokine-induced iNOS activity in A172 cells (Fig. 1). The
reduction in iNOS activity mediated by β-FNA was not a consequence of cytotoxicity, as no
differences in viability were detected among the concentrations tested (Fig. 1). Also, control
experiments confirmed that β-FNA did not interfere with the nitrite assay and had no effect
on nitrite detection (data not shown).
β-FNA effects on NOS2 mRNA expression
Minimal NOS2 mRNA expression was detected in unstimulated control cells as revealed by
qRT-PCR (Fig. 2). Conversely, 8 h cytokine exposure resulted in a marked induction of
NOS2 mRNA expression. Cytokine-induced NOS2 mRNA expression was significantly
inhibited in the presence of 11 μM β-FNA (Fig. 2). Exposure to β-FNA alone for 8 h had no
effect on NOS2 mRNA expression in A172 cells.

Discussion
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Astroglia are a major source of iNOS expression and NO production in the brain, and
extensive and/or prolonged iNOS expression is presumably instrumental in
neuropathogenesis (Louin et al. 2006). In the present study, iNOS activation was assessed
through measurement of nitrite accumulation in the media (which only occurs in these cells
after iNOS expression) and at the level of NOS2 mRNA expression. Details on the time
course of cytokine-induced iNOS expression in A172 cells, at the level of mRNA and
protein, have been discussed in a previous report (Davis and Syapin 2004). Likewise,
cytokine-stimulated iNOS activity in A172 cells as measured by nitrite accumulation and the
citrulline conversion assay has been characterized by our group (Davis et al. 2002; Davis
and Syapin 2004).
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Ablation of iNOS induction prevents neuropathogenesis (Jafarian-Tehrani et al. 2005; Louin
et al. 2006). In particular, opioids such as morphine have neuroprotective properties (Zhao et
al. 2006). While the mechanism for the neuroprotective effects of morphine are not
completely understood, under certain conditions, morphine attenuates oxidative and
proinflammatory stress (Lee et al. 2004). In our human astroglial model, we found that
morphine (≥1 mM) and the more potent MOR agonist, fentanyl (≥0.2 mM) only inhibited
iNOS expression at relatively high, biologically irrelevant concentrations (data not shown).
Interestingly, the MOR antagonist, β-FNA failed to block the inhibitory actions of fentanyl
(data not shown). However, this is the first report to demonstrate that β-FNA dosedependently inhibits iNOS activity in astroglial cells. Inhibition of NOS2 mRNA expression
by β-FNA suggests that iNOS activation is inhibited transcriptionally or pretranscriptionally, yet the details remain to be elucidated. Given that the MOR selective
antagonist, β-FNA, did not block fentanyl-mediated inhibition of iNOS activity suggests a
MOR-independent mechanism.
The anti-inflammatory actions of β-FNA identified in this study support and add to the
findings of others (Liu et al. 2000), which have identified MOR-independent, antiinflammatory actions of the non-specific opioid receptor antagonist, naloxone. For example,
both the MOR inactive stereoisomer (+)-naloxone and (−)-naloxone reduced inflammatoryinduced damage of rat dopaminergic neurons, suggesting a potential therapeutic role in the
treatment of Parkinson’s disease (Liu et al. 2000). More recently, this same group
determined that Aβ (1–42)-induced neurotoxicity was reduced by naloxone in an opioid
receptor-independent mechanism (Liu et al. 2002). It was determined that the
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neuroprotective effects of naloxone were due to reduced microglial superoxide production
(Liu et al. 2002).
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Astroglia express all four opioid receptor types (mu, kappa, delta, and nociceptin/orphanin
FQ), and these receptors are differentially expressed among brain regions (Ruzicka et al.
1995; Zhao et al. 2002). We recently determined that human MOR (hMOR) is expressed in
A172 cells after TNFα exposure (preliminary data). Thus, it is possible that inhibition of
iNOS induction results from β-FNA action at a receptor other than MOR. For instance,
depending on the opioid receptor type, β-FNA can exhibit initial KOR agonist activity and
then irreversibly bound antagonist activity at MOR (Qi et al. 1990).
Maximal induction of iNOS in A172 cells requires NF-κB activation, as demonstrated via
pharmacologic inhibition of iNOS activation with two mechanistically distinct NF-κB
inhibitors (MG-132 and helenalin, data not shown). We recently found that translocation of
the p65 subunit of the transcription factor NF-κB into the nucleus is inhibited by β-FNA
(Davis et al. 2007). Thus, it may be that β-FNA inhibits iNOS induction through modulation
of NF-κB expression or function; however, further investigation is needed.
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In summary, the neuroprotective properties of opioid compounds are not completely
understood, but both MOR-dependent and MOR-independent mechanisms are likely
involved. Regarding therapeutic potential, β-FNA is particularly attractive given it is a safe,
non-addictive opioid agent that readily enters the CNS. A better understanding of the
mechanism governing the anti-inflammatory actions of β-FNA may provide clues for
development of therapeutic strategies to combat pathologies in the CNS associated with
neuroinflammation.

Acknowledgments
This work was supported in part by NIH grants AA 014955 (RLD) and DA 012448 (CWS).

References

NIH-PA Author Manuscript

Davis RL, Syapin PJ. Acute ethanol exposure modulates expression of inducible nitric-oxide synthase
in human astroglia: evidence for a transcriptional mechanism. Alcohol. 2004; 32:195–202.
[PubMed: 15282113]
Davis RL, Dertien J, Syapin PJ. Ethanol-induced modulation of inducible nitric-oxide synthase activity
in human A172 astrocytoma cells. Alcohol Clin Exp Res. 2002; 26:1404–1411. [PubMed:
12351936]
Davis RL, Buck DJ, Saffarian N, Stevens CW. The opioid antagonist, beta-funaltrexamine, inhibits
chemokine expression in human astroglial cells. J Neuroimmunol. 2007; 186:141–149. [PubMed:
17475341]
Hettinger AM, Allen MR, Zhang BR, Goad DW, Malayer JR, Geisert RD. Presence of the acute phase
protein, bikunin, in the endometrium of gilts during estrous cycle and early pregnancy. Biol Reprod.
2001; 65:507–513. [PubMed: 11466219]
Jafarian-Tehrani M, Louin G, Royo NC, Besson VC, Bohme GA, Plotkine M, Marchand-Verrecchia
C. 1400W, a potent selective inducible NOS inhibitor, improves histopathological outcome
following traumatic brain injury in rats. Nitric Oxide. 2005; 12:61–69. [PubMed: 15740979]
Lee J, Kim MS, Park C, Jung EB, Choi DH, Kim TY, Moon SK, Park R. Morphine prevents
glutamate-induced death of primary rat neonatal astrocytes through modulation of intracellular
redox. Immunopharmacol Immunotoxicol. 2004; 26:17–28. [PubMed: 15106729]
Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage
through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther. 2000;
293:607–617. [PubMed: 10773035]

J Neuroimmune Pharmacol. Author manuscript; available in PMC 2011 March 23.

Davis et al.

Page 6

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Liu Y, Qin L, Wilson BC, An L, Hong JS, Liu B. Inhibition by naloxone stereoisomers of betaamyloid peptide (1–42)-induced superoxide production in microglia and degeneration of cortical
and mesencephalic neurons. J Pharmacol Exp Ther. 2002; 302:1212–1219. [PubMed: 12183682]
Louin G, Marchand-Verrecchia C, Palmier B, Plotkine M, Jafarian-Tehrani M. Selective inhibition of
inducible nitric oxide synthase reduces neurological deficit but not cerebral edema following
traumatic brain injury. Neuropharmacology. 2006; 50:182–190. [PubMed: 16242164]
Marchetti B, Serra PA, Tirolo C, L’Episcopo F, Caniglia S, Gennuso F, Testa N, Miele E, Desole S,
Barden N, Morale MC. Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to
experimental parkinsonism: pivotal role for glia-neuron interactions. Brain Res Brain Res Rev.
2005; 48:302–321. [PubMed: 15850669]
Poluektova L, Meyer V, Walters L, Paez X, Gendelman HE. Macrophage-induced inflammation
affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis.
Glia. 2005; 52:344–353. [PubMed: 16078235]
Qi JA, Heyman JS, Sheldon RJ, Koslo RJ, Porreca F. Mu antagonist and kappa agonist properties of
beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice. J Pharmacol Exp
Ther. 1990; 252:1006–1011. [PubMed: 2156986]
Ruzicka BB, Fox CA, Thompson RC, Meng F, Watson SJ, Akil H. Primary astroglial cultures derived
from several rat brain regions differentially express mu, delta and kappa opioid receptor mRNA.
Brain Res Mol Brain Res. 1995; 34:209–220. [PubMed: 8750824]
Zhao H, Huang HW, Wu GC, Cao XD. Effect of orphanin FQ on interleukin-1beta mRNA transcripts
in the rat CNS. Neuroscience. 2002; 114:1019–1031. [PubMed: 12379256]
Zhao P, Huang Y, Zuo Z. Opioid preconditioning induces opioid receptor-dependent delayed
neuroprotection against ischemia in rats. J Neuropathol Exp Neurol. 2006; 65:945–952. [PubMed:
17021399]

NIH-PA Author Manuscript
J Neuroimmune Pharmacol. Author manuscript; available in PMC 2011 March 23.

Davis et al.

Page 7

NIH-PA Author Manuscript

Fig. 1.
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β-Funaltrexamine dose-dependently inhibits cytokine-stimulated nitrite production A172
cells. Astroglial cells were exposed for 24 h to a cytokine mixture containing IFNγ (100 ng/
ml), IL-1β (5 ng/ml), and TNFα (30 ng/ml) in the presence or absence of 0.05–33 μM βFNA. Nitrite accumulation (top panel) in the culture media was determined
spectrophotometrically using the Griess reagent. Cell viability (bottom panel) was assessed
using the MTT assay. The curve was generated by nonlinear regression in which the Hill
slope was not constrained. Data points represent the mean ± SEM of duplicate measures
from four to eight independent experiments
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Fig. 2.

β-Funaltrexamine inhibits cytokine-stimulated NOS2 mRNA expression in A172 cells.
Astroglial cells were exposed for 8 h to a cytokine mixture containing IFNγ (100 ng/ml),
IL-1β (5 ng/ml) and TNFα (30 ng/ml) in the presence or absence of 11 μM β-FNA. NOS 2
mRNA expression was measured using qRT-PCR and is expressed as fold change. qRTPCR was performed using SYBR green reporter assay. The mean ΔCT value obtained after
normalization with 18S for unstimulated cells was used as a baseline for comparing NOS2
gene expression among treatments. Results are presented as least square means + standard
error of the mean
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